Lipid parameters, doses and blood levels of calcineurin inhibitors in renal transplant patients

Indian Journal of Clinical Biochemistry

Volumn 28, Issue 2, 2013, Pages 164-168

  Ciftci, Hayriye Senturk ^a   Ayna, Tulay Kilicaslan ^b   Calıskan, Yasar Kerem ^c   Turkmen, Aydin ^c   Gurtekin, Mehmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Calcineurin inhibitors; Cardiovascular diseases; Lipid metabolism; Renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CHOLESTEROL; CYCLOSPORIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DYSLIPIDEMIA; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84891831055     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-012-0251-6     Document Type: Article

References (13)

1. Thomson W, Starzl TE Immunosuppressive drugs: developments in anti-rejection. London: Edward Arnold; 1994. p. 235.
2. Thomson W. FK 506-How much potential? Immunol Today. 1989;10:6-10.
3. Calne RY. Immunosuppression in liver transplantation. N Engl J Med. 1994;331:1154-5.
4. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc. 2004;36(2):25-32.
5. Goto T, Kino T, Hatanaka H, Nishiyama M, Okuhara M, Kohsaka M, et al. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukabaensis. Transplant Proc. 1987;6(91):4-8.
6. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK 506, a novel immunosuppressant isolated from a Streptomyces:I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40:1249-55.
7. Wanner C, Quaschning T. Abnormal lipid metabolism after renal transplantation. Ann Transplant. 2001;6(1):5-8.
8. Ligtenberg G, Hene RJ, BlankestIjn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol. 2001;12:368-73.
9. Nemati E, Einollahi B, Taheri S, Moghani LM, Kalantar E, Simforoosh N, et al. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss? Transplant Proc. 2007;39(4):1223-4.
10. Badiou S, Cristol JP, Mourad G. Dyslipidemia following kidney transplantation: diagnosis and treatment. Curr Diab Rep. 2009;9:305-11.
11. Quaschning T, Mainka T, Nauck M, Christian LR, Wanner C, Kramer-Guth A. Immunosuppression enhances atherogenicity of lipid profile after transplantation. Kidney Int. 1999;56(71):235-7.
12. Colak T, Karakayali, Yagmurdur MC, Moray G. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. Transplant Proc. 2002;34:2081-2.
13. Kuster GH, Bartucci MR, Mayes JT, Schulac JA. The effects of cyclosporine and prednisone on serum lipid and (apo) lipoprotein levels in renal transplant recipients. J Am Soc Nephrol. 1995;5:2077.